

# Index

- Accelerated fractionation, 73, 76–79  
 hyperfractionated, split-course irradiation with, 79, 80  
 regenerative response of tumor and, 73–74  
 schedules with, 76, 77  
 techniques with, 76–79
- N-acetylmuramyl dipeptide (MDP), 163
- Acoustic neuroma, on magnetic resonance imaging (MRI), 116–117, 124
- Actinomycin D, with orbital rhabdomyosarcoma (RMS), 224, 235–236
- Adenocarcinoma, and retinoids, 181
- Adriamycin  
 lymphoma of extranodal head and neck sites and, 279  
 orbital rhabdomyosarcoma (RMS) and, 228
- Albumin levels, and head and neck cancer, 178
- Alcohol, as cocarcinogen, 178
- Alkaline phosphatase, with lymphoma of extranodal head and neck sites, 274
- Alpha interferon (IFN), 169, 171, 172
- Alveolar orbital rhabdomyosarcoma (RMS), 226
- Ann Arbor Staging System, 275–276
- Anterior neck dissection, 24–25
- Antibiotic regime, in mandibular reconstruction, 3
- Argon tunable dye laser system, 67–68
- Arytenoid cancer  
 extended vertical partial laryngectomy in, 32  
 supraglottic laryngectomy in, 52, 53
- Arytenoid unity, in laryngeal reconstruction, 49
- Bacillus Calmette-Guerin (BCG)  
 cutaneous melanomas of the head and neck with, 255, 256  
 immunomodulation with, 163
- Basal cell carcinoma  
 pigmented, 247  
 retinoids and, 182
- Base of tongue cancer  
 brachytherapy in, 96–100  
 extended supraglottic laryngectomy in, 55  
 lymphoma of extranodal head and neck sites and, 270  
 supraglottic laryngectomy in, 55
- BCNU, with cutaneous melanomas of the head and neck, 257
- Benzo (a)pyrene, 177–178, 181
- Beta interferon (IFN), 169, 170, 171–172
- Bilateral vertical hemilaryngectomy, 51–52
- Biostatistics, 193–220  
 allocation of treatments to patients in, 204–209  
 basic components of successful, 193  
 choice of patients for analysis in, 214  
 comparability among subsets in, 214  
 comparison of medians in, 212–213  
 confidence interval calculation in, 211–212  
 example of use of, 213–215  
 factorial design of, 195–198  
 historical controls used in, 194  
 log rank test in, 213  
 patient follow-up in, 216  
 planning of phase III clinical trials with, 194–198  
 pragmatic and explanatory trials in, 216  
 product-limit method in, 210–211  
 pure randomization in treatment allocation in, 205  
 randomization weighting in, 208–209  
 random permuted block design in, 206–207  
 sample size requirements in, 198–204

- statistical analysis of failure in, 209–216
  - treatment-covariate interaction in, 216–220
- Bleomycin
  - combination chemotherapy with, 146, 149
  - cutaneous melanomas of the head and neck with, 257
  - lymphoma of extranodal head and neck sites and, 279
- B lymphocytes, and lymphoma of extranodal head and neck sites, 273–274
- BOLD combination chemotherapy, with cutaneous melanomas of the head and neck, 257
- Bone grafts, in mandibular reconstruction, 2, 7–8
- Bone marrow biopsies, with lymphoma of extranodal head and neck sites, 274–275
- Botryoid orbital rhabdomyosarcoma (RMS), 226–227
- Brachytherapy, 93–104
  - base of tongue carcinoma with, 96–100
  - cervical region with, 101–102
  - combined modality treatment with, 103–104
  - dosimetry in, 103
  - hypoxic cell sensitizing drugs with, 103
  - isodose distributions in, 103
  - oral cavity lesions with, 96
  - oropharyngeal lesions with, 96–101
  - radioactive isotopes used in, 93–95
  - tonsillo-palatine implants in, 100–101
- Breast cancer
  - argon tunable dye laser system in, 67
  - lymph node immunoreactivity in, 162
- Bronchial adenocarcinoma, and retinoids, 181
- Bronchoscopic laser surgery, 67
- Burkitt's lymphoma, 168
- Calcium phosphate, in mandibular reconstruction, 3
- Carbon dioxide laser, 62–66
  - advantages of, 65
  - airway reestablishment with, 64
  - early use of, 61–62
  - excisional biopsy with, 64
  - external beam radiation therapy compared with, 65
  - laryngeal carcinoma with, 62, 63–65
  - neodymium (Nd): YAG laser used with, 67
  - oral cavity carcinoma with, 65–66
- CCNU, with cutaneous melanomas of the head and neck, 257
- Central nervous system, with lymphoma of extranodal head and neck sites, 275
- Cephalosporin, in mandibular reconstruction, 3
- Cervical adenopathy
  - lymphoma of extranodal head and neck sites with, 269
  - magnetic resonance imaging (MRI) in, 139
- Cervical dysplasia, and retinoids, 182
- Cervical lymph node
  - extracapsular spread (ECS) of metastatic squamous carcinoma prognosis and size of, 13–15
  - head and neck malignancies and role of, 155
  - immunoreactivity of, 159–163
  - normal anatomy of, 155–156
- Cervical lymph node metastasis
  - cervical neck node involvement in, 156–157
  - cutaneous melanomas of the head and neck with, 253–255
  - extracapsular spread (ECS) of, *see* Extracapsular spread (ECS) of squamous carcinoma in cervical metastasis
  - staging system in, 163
- Cervical neck tumors, and brachytherapy, 101–102
- Cesium (Ce) brachytherapy, 93, 95
- Chemotherapy
  - brachytherapy with, 103–104
  - cutaneous melanomas of the head and neck with, 256–257
  - extent of radical resection and, 150–152
  - immunosuppressive nature of, 157
  - lymphoma of extranodal head and neck sites and, 279, 280, 281
  - multi-modality treatment with, 148–152
  - orbital rhabdomyosarcoma (RMS) and, 224, 235–236
  - patient refusal of surgery and, 150
  - radiation therapy combined with, 148
  - see also* Combination chemotherapy and *specific drugs*
- Chlorambucil, with lymphoma of extranodal head and neck sites, 280
- Chlorozotacin, with cutaneous melanomas of the head and neck, 257
- Chondrosarcoma
  - extended vertical partial laryngectomy in, 34
  - magnetic resonance imaging (MRI) in, 121
- CHOP combination chemotherapy, with lymphoma of extranodal head and neck sites, 279
- Cisplatin
  - combination chemotherapy with, 145, 146, 149, 151

- single-agent chemotherapy with, 144
- 13-cis retinoic acid, and oral leukoplakia, 184
- Clinical trial design, 193–200
  - allocation of treatments to patients in, 204–209
  - basic components of successful, 193
  - choice of patients for analysis in, 214
  - comparability among subsets in, 214
  - comparison of medians in, 212–213
  - confidence interval calculation in, 211–212
  - example of, 213–215
  - factorial design of, 195–198
  - historical controls used in, 194
  - log rank test in, 213
  - patient follow-up in, 216
  - planning of phase III, 194–198
  - pragmatic and explanatory trials in, 216
  - product-limit method in, 210–211
  - pure randomization in treatment allocation in, 205
  - randomization weighting in, 208–209
  - random permuted block design in, 206–207
  - sample size requirements in, 198–204
  - statistical analysis of failure in, 209–216
  - treatment-covariate interaction in, 216–220
- Clonogenic assay for T lymphocyte evaluation, 159–162
- COB combination chemotherapy, 146
- Combination chemotherapy
  - adequate radiotherapy with, 144
  - adequate resection with, 144
  - complete response (CR) in, 146
  - cutaneous melanomas of the head and neck with, 257
  - defining best choice in, 145–146
  - lymphoma of extranodal head and neck sites and, 279, 280
  - multi-modality treatment with, 148–152
  - radiotherapy combined with, 148
  - stage of disease and, 146–148
  - timing of, 146
- Compound nevi, 247
- Computed tomography (CT)
  - cervical adenopathy on, 139, 140
  - cutaneous melanomas of the head and neck with, 249
  - hypopharyngeal and laryngeal malignancies on, 130
  - lymphoma of extranodal head and neck sites and, 274
  - magnetic resonance imaging (MRI) compared with, 107–108
  - nasopharyngeal carcinoma on, 124
  - oropharynx and floor of mouth on, 126
  - paranasal sinuses on, 134, 135
  - salivary gland tumors on, 132, 134
  - skull base on, 116
  - thoracic inlet tumors on, 137
  - thyroid and parathyroid glands with, 137
- Conductive hearing loss, and magnetic resonance imaging (MRI), 124
- Conjunctiva lymphoma, 272
- Cord fixation glottic cancer, 33
- CT, *see* Computed tomography (CT)
- Cutaneous melanomas of the head and neck, 245–261
  - chemotherapy in, 256–257
  - classification of, 247–248
  - definitive diagnosis of, 248–252
  - differential diagnosis in, 246–247
  - epidemiology and etiology of, 245–246
  - hormonal therapy in, 257–258
  - immunotherapy in, 255–256
  - incidence of, 245
  - levels of tumor invasion in, 250
  - palliative treatment in, 260
  - radiotherapy in, 258–259, 260
  - regional lymph node treatment in, 253–255
  - staging system in, 250–252
  - sun exposure and, 246
  - surgery for, 252–255
- CVP combination chemotherapy, with lymphoma of extranodal head and neck sites, 280
- Cyclophosphamide
  - lymphoma of extranodal head and neck sites and, 279, 280
  - orbital rhabdomyosarcoma (RMS) and, 235–236
- Cyst fluid, on magnetic resonance imaging (MRI), 115
- Dacron mesh crib, in mandibular reconstruction, 4
- Dermal nevi, 247
- Dermatofibromas, 247
- Dexamethasone, with lymphoma of extranodal head and neck sites, 279
- Diethylstilbestrol, with cutaneous melanomas of the head and neck, 258
- Dihematoporphyrin ether, 68
- Dimethyl triazene imidazole carboxamide (DTIC), with cutaneous melanomas of the

- head and neck, 257
- Dinitrochlorobenzene (DNCB), with cutaneous melanomas of the head and neck, 255
- DOPA studies, with cutaneous melanomas of the head and neck, 258
- Embryonal orbital rhabdomyosarcoma (RMS), 225–226
- Epstein-Barr virus (EBV)
- head and neck cancer and, 178
  - interferon treatment and, 170, 172
  - nasopharyngeal carcinoma and, 168–169
- Esophageal cancer, and lower neck dissection, 25
- Estramustine, with cutaneous melanomas of the head and neck, 258
- Estrogen, with cutaneous melanomas of the head and neck, 258
- Extended partial laryngeal surgery, 31–58
- Extended supraglottic laryngectomy (ESGL), 55–57
- radiation combined with, 57
  - surgical techniques in, 55–57
- Extended vertical partial laryngectomy (EVPL), 32–52
- arytenoid unity in, 49
  - contraindications for, 34–35
  - glottic carcinoma with, 43–44
  - indications for, 32–34
  - problems encountered in, 32
  - radiation therapy after, 45
  - recurrence of cancer after, 32, 50
  - results with, 49–52
  - surgical reconstruction after, 45–49
  - technique of, 35–45
  - three-quarters extended, 33, 44–45
- Extracapsular spread (ECS) of squamous carcinoma in cervical metastasis, 11–20
- clinical assessment of extent of disease and histologic findings in, 19
  - lymph node size and, 13–15
  - multiple nodes in, 12
  - modified neck dissection with radiation in, 27–28
  - prognosis in, 13
  - staging of, 13, 19
  - surgery plus postoperative radiation therapy for, 18
  - survivorship in, 15–17
  - tumor differentiation in, 12
- Eyelid rhabdomyosarcoma, *see* Orbital rhabdomyosarcoma
- Fenestrated strut, in mandibular reconstruction, 3–4
- Fifth nerve neuroma, on magnetic resonance imaging (MRI), 119–120
- Flagyl, in mandibular reconstruction, 3
- Flaps in mandibular reconstruction
- myocutaneous, 2, 3, 6
  - osteomyocutaneous, 6–7
  - pectoralis osteomyocutaneous, 6
  - trapezius scapular osteomyocutaneous, 6–7
- Floor of mouth tumors, and magnetic resonance imaging (MRI), 126
- 5-fluorouracil (5-FU), in combination therapy, 146, 149, 151
- Free bone grafts, in mandibular reconstruction, 2, 7–8
- Freeze dried bone, in mandibular reconstruction, 5
- Functional neck dissection, 22–23
- Gamma glytamyl transpeptidase (GGTP), with cutaneous melanomas of the head and neck, 249
- Gamma interferon (IFN), 169
- Glomus tumors, on magnetic resonance imaging (MRI), 118–124
- Glottic larynx cancer
- carbon dioxide laser in, 63–65
  - extended vertical partial laryngectomy in, 33, 43–44
  - functional neck dissection in, 23
- Hashimoto's thyroiditis, 272
- Head and neck cancer
- clinical trial design in, 193–220
  - immunoreactivity of, 157
  - natural history of, 177–179
- Hearing loss, and magnetic resonance imaging (MRI), 124
- Hemangioma, 247
- Hemilaryngectomy, bilateral vertical, 51–52
- Hemorrhage, on magnetic resonance imaging (MRI), 116
- Herpes simplex virus type I, as cancer initiator, 178
- Herpes-virus associated neoplasm, 169, 179
- Hormonal therapy, with cutaneous melanomas of the head and neck, 257–258
- Horner's syndrome, 138
- Hyperbaric oxygen, in mandibular reconstruction, 3

- Hyperfractionated radiotherapy, 73, 74–76  
 accelerated, split-course irradiation with, 79, 80  
 clinical trials with, 74–76  
 redistribution of tumor cells with, 73  
 schedules for, 74, 75
- Hyperthermia, with brachytherapy, 104
- Hypopharyngeal cancer  
 anterior neck dissection in, 24  
 magnetic resonance imaging (MRI) in, 130  
 radiation therapy timing in, 143  
 radiation therapy with multiple fractions in, 82–88  
 supraomohyoid neck dissection in, 23  
 Hypoxic cell sensitizing drugs, with brachytherapy, 103
- Iliac free bone graft, in mandibular reconstruction, 7–8
- Immunology  
 clonogenic assay for T lymphocyte evaluation in, 159–162  
 head and neck cancer and, 157  
 histologic staging with, 163  
 lymphoma of extranodal head and neck sites and, 273–274  
 modulation of response in, 163  
 pathogenesis and progression of cancer and, 178–179  
 recurrent cancer and, 162  
 regional immune response in, 159, 162  
 treatment implications of response in, 163–164
- Immunotherapy, with cutaneous melanomas of the head and neck, 255–256
- Interferon (IFN)  
 as anti-neoplastic agent, 169  
 clinical trials with, 171–172  
 nasopharyngeal carcinoma treatment and, 170–172  
 species of, 169
- Involucrin, and retinoids, 185
- Iodine (I) brachytherapy, 93–95  
 cervical region with, 101–102  
 dosimetry in, 103
- Iridium (IR) brachytherapy, 93  
 base of tongue carcinoma with, 97–100  
 cervical region with, 101, 102  
 dosimetry in, 103  
 implantable needles with, 95  
 microwave hyperthermia with, 104  
 oral cavity lesions with, 96  
 oropharyngeal lesions with, 96–101  
 tonsillo-palatine implants in, 100–101
- Isotopes in therapy, *see* Brachytherapy
- Juvenile laryngeal papillomatosis, 169
- Keratinocyte growth, and retinoids, 180
- Lactic dehydrogenase (LDH)  
 cutaneous melanomas of the head and neck with, 249  
 lymphoma of extranodal head and neck sites and, 274
- Laryngeal carcinoma  
 anterior neck dissection in, 24  
 brachytherapy implants in, 95  
 carbon dioxide laser in, 62, 63–65  
 functional neck dissection in, 23  
 head and neck cancer and development of secondary, 179  
 lymphoma of extranodal head and neck sites and, 270  
 magnetic resonance imaging (MRI) in, 126, 130  
 mortality rate for, 177  
 multimodality therapy in, 151  
 radiation therapy with multiple fractions in, 82–88  
 supraomohyoid neck dissection in, 23  
 therapeutic options for, 32
- Laryngeal papillomatosis, 169
- Laryngeal sarcoma, 32
- Laryngectomy  
 early use of, 31  
*see also* Extended supraglottic laryngectomy (ESGL); Extended vertical partial laryngectomy (EVPL); Partial laryngeal surgery
- Laryngoplasty, 45–49
- Laser surgery, 61–68  
 advantages of, 65  
 airway reestablishment with, 64  
 argon tunable dye system in, 67–68  
 carbon dioxide laser in, 62–66  
 early use of, 61–62  
 excisional biopsy with, 64  
 external beam radiation therapy combined with, 65  
 laryngeal carcinoma with, 62, 63–65  
 Nd:YAG laser in, 66–67  
 oral cavity carcinoma with, 65–66
- Lateral neck dissection, 25

- Lentigo maligna (LM), 259
- Lentigo maligna melanoma (LMM), 247–248, 259
- Leukoplakia, and retinoids, 182–184
- Liver function tests
- cutaneous melanomas of the head and neck with, 249
  - lymphoma of extranodal head and neck sites and, 274
- Log rank test, 213
- Lower neck dissection, 25–26
- Lung cancer, and argon tunable dye laser system, 67
- Lung metastases
- partial laryngectomy plus lobectomy for, 32
  - retinoids and, 182
- Lymphadenectomy
- frozen sections in, 26–27
  - use of regional, 22
- Lymphangiography, in cutaneous melanomas of the head and neck, 249
- Lymph node malignancies
- brachytherapy implants in, 95
  - cutaneous melanomas of the head and neck with, 253–255
  - immunology of, 155–164
  - magnetic resonance imaging (MRI) in, 114–115
  - orbital rhabdomyosarcoma (RMS) and, 225
- Lymph node system
- breast cancer and immunoreactivity of, 162
  - orbital rhabdomyosarcoma (RMS) and, 225
  - see also* Cervical lymph node
- Lymphoblastic lymphoma, 280
- Lymphoma of extranodal head and neck sites, 269–282
- clinical presentations in, 269–271
  - histologic classification of, 271–274
  - immunohistochemistry of, 273–274
  - pretreatment evaluation of, 274–278
  - staging system for, 275–276
  - therapy for, 277–281
- Lymphoscintigraphy, in cutaneous melanomas of the head and neck, 249–250
- Magnetic resonance imaging (MRI), 107–141
- acoustic neuromas with, 116–117, 124
  - basic principles of, 108–116
  - benign neck lesions in, 130
  - cervical adenopathy on, 139
  - clinical imaging with, 116–140
  - computed tomography (CT) compared with, 107–108
  - conductive hearing loss on, 124
  - cyst fluid with, 115
  - echo delay time in, 109
  - future trends in, 140
  - glomus tumors on, 118–124
  - Huntington Medical Research Institutes (HMRI) experience with, 104–142
  - hypopharyngeal carcinoma on, 130
  - intensity calculation in, 110
  - laryngeal carcinoma on, 126, 130
  - magnetic relaxation times in, 108–109
  - malignant lymph nodes with, 114–115
  - nasopharyngeal carcinoma on, 124–126
  - normal appearance of various tissues with, 110–111, 116
  - oropharynx, tongue, and floor of mouth on, 126
  - paranasal sinuses on, 134–135
  - parapharyngeal tumor on, 126
  - patient motion in, 130
  - repetition time in, 109
  - salivary gland tumors on, 132–134
  - signal intensity range of pathological lesions in, 111–115
  - skull base on, 116–124
  - subacute hemorrhage on, 116
  - thyroid and parathyroid gland tumors on, 137
- Malnutrition, and head and neck cancer, 178
- Mandibular reconstruction, 1–9
- advantages and disadvantages of, 8
  - antibiotic regime in, 3
  - free flaps used in, 2, 7–8
  - freeze dried bone used in, 5
  - general concepts in, 2–3
  - goals of, 1
  - mesh cribs used in, 4
  - methods for, 3–8
  - osteomyocutaneous flaps in, 6–7
  - radiation therapy after, 5
- M-BACOD combination chemotherapy, with lymphoma of extranodal head and neck sites, 279
- Medroxy progesterone acetate, with cutaneous melanomas of the head and neck, 258
- Melanoma
- cutaneous, *see* Cutaneous melanomas of the head and neck
  - incidence of, 245
  - posterior-lateral neck dissection in, 25

- sun exposure and, 246
- Mesh cribs, in mandibular reconstruction, 4
- Metastasis
  - cervical neck node involvement in, 156–157
  - extracapsular spread (ECS) of, *see* Extracapsular spread (ECS) of squamous carcinoma in cervical metastasis
  - cutaneous melanomas of the head and neck with, 253–255
  - nasopharyngeal carcinoma and, 167–168
  - orbital rhabdomyosarcoma (RMS) and, 225
- partial laryngectomy plus lobectomy with, 32
- recurrence of head and neck cancer and, 179
- skull base, 117
- Methyl CCNU, with cutaneous melanomas of the head and neck, 257
- Microwave hyperthermia, with brachytherapy, 104
- Modified neck dissection, 21–29
  - anterior, 24–25
  - definition of, 21–26
  - functional, 22–23
  - lower, 25–26
  - pathology reports in, 26–27
  - posterior-lateral, 25
  - preserving anatomic structures in neck in, 22
  - radiation after, 27–28
  - supraomohyoid, 23
  - suprahyoid, 23
- MRI, *see* Magnetic resonance imaging (MRI)
- Mucosal abnormalities, and tobacco usage, 177–178
- Mycosis fungoides, and retinoids, 182
- Myelodysplastic syndrome, and retinoids, 182
- Myocutaneous flaps, in mandibular reconstruction, 2, 3, 6–7
- Nasopharyngeal carcinoma (NPC)
  - brachytherapy implants in, 95
  - Epstein-Barr virus (EBV) and, 168–169
  - frequency of, 167
  - interferon and, 169–172
  - lymphoma of extranodal head and neck sites and, 270
  - magnetic resonance imaging (MRI) in, 124–126
  - metastases from, 167–168
  - posterior-lateral neck dissection in, 25
  - risk factors in, 167
- Neodymium (Nd)-in-glass laser, 61
- Neodymium (ND): YAG laser, 66–67
- Nevi, 246–247
- Nodular melanoma (NM), 247–248
- Nominal standard dose (NSD) formula, 71
- Non-Hodgkin's lymphoma, *see* Lymphoma of extranodal head and neck sites
- Nutritional deficiency, and head and neck cancer, 178
- Oncovin, in combination chemotherapy, 146
- Oral cavity carcinoma
  - brachytherapy in, 95, 96
  - carbon dioxide laser in, 65–66
  - functional neck dissection in, 23
  - lymphoma of extranodal head and neck sites and, 270
  - magnetic resonance imaging (MRI) in, 126
  - supraomohyoid neck dissection in, 23
- Orbital lymphoma, 280–281
- Orbital rhabdomyosarcoma (RMS), 223–240
  - alveolar, 226
  - botryoid, 226–227
  - chemotherapy for, 235–236
  - clinical manifestations of, 227–228
  - diagnostic evaluation of, 228–230
  - embryonal, 225–226
  - etiology of, 225
  - history of, 223–224
  - incidence of, 224
  - normal and tumor anatomy in, 225
  - pathology of, 225–227
  - pleomorphic, 227
  - population characteristics in, 230
  - radiation therapy for, 231–235
  - relapses in, 238
  - staging system for, 229–230
  - subtypes of, 225–227
  - surgery for, 230–231
  - treatment results in, 237–240
- Oropharynx carcinoma
  - brachytherapy in, 95, 96–101
  - extracapsular spread (ECS) of squamous carcinoma in cervical metastasis in, 12
  - functional neck dissection in, 23
  - head and neck cancer and development of secondary, 179
  - hyperfractionated radiotherapy for, 76
  - magnetic resonance imaging (MRI) in, 126
  - radiation therapy with multiple fractions in, 82–88
  - supraomohyoid neck dissection in, 23
- Osteomyocutaneous flaps, in mandibular recon-

- truction, 6–7
- Oxygen administration, in mandibular reconstruction, 3
- Pancoast tumor, on magnetic resonance imaging (MRI), 138
- Papilloma virus, and head and neck cancer, 178
- Papova-virus associated neoplasm, 169
- Paranasal sinuses
  - lymphoma of extranodal head and neck sites and, 275
  - magnetic resonance imaging (MRI) and, 123–137
  - Parapharyngeal space, on magnetic resonance imaging (MRI), 126
  - Parathyroid glands, on magnetic resonance imaging (MRI), 137
- Parotid gland tumors
  - magnetic resonance imaging (MRI) in, 132–134
  - orbital rhabdomyosarcoma (RMS) and, 225
- Partial laryngeal surgery
  - early work with, 31
  - goal of, 31
  - recurrence of cancer and, 50
  - results with, 49–52
  - see also* Extended supraglottic laryngectomy (ESGL); Extended vertical partial laryngectomy (EVPL)
- Pectoralis osteomyocutaneous flaps, in mandibular reconstruction, 6
- Pigmented basal cell carcinoma, 247
- Pigmented seborrheic keratoses, 247
- Piriform sinus cancer
  - extended vertical partial laryngectomy in, 34
  - supraglottic laryngectomy in, 52, 53
- Pleomorphic orbital rhabdomyosarcoma (RMS), 227
- Polyethylene materials, in mandibular reconstruction, 3
- Polyurethane mesh crib, in mandibular reconstruction, 4
- Posterior-lateral neck dissection, 25
- Prednisone, with lymphoma of extranodal head and neck sites, 279, 280
- Pregnanetrione, with cutaneous melanomas of the head and neck, 258
- Premalignant lesions, and retinoids, 182
- Radiation therapy
  - anterior neck dissection with, 24
  - carbon dioxide laser compared with, 65
  - chemotherapy combined with, 148
  - cutaneous melanomas of the head and neck with, 258–259, 260
  - extended supraglottic laryngectomy combined with, 57
  - extended vertical partial laryngectomy with, 45
  - extracapsular spread (ECS) of squamous carcinoma in cervical metastasis and, 18
  - hypopharyngeal cancer and timing of, 143
  - immunosuppressive nature of, 157
  - lymphoma of extranodal head and neck sites and, 278–279, 280, 281
  - mandibular reconstruction followed by, 5
  - modified neck dissection with, 27–28
  - orbital rhabdomyosarcoma (RMS) and, 224, 231–235
  - radiosensitizers and radioprotectors in, 152
  - recurrent laryngeal carcinoma after, 32, 34
  - unresectable cancer with, 144
- Radiation Therapy Oncology Group (RTOG) hyperfractionation radiotherapy scheme, 81–82
- Radiation therapy with multiple fractions, 71–88
  - accelerated fractionation in, 73, 76–79
  - accelerated, hyperfractionated, split-course, 79, 80
  - acute tolerance in, 83
  - clinical experience with, 74–82
  - complications with, 87–88
  - convenience with, 71–72
  - hyperfractionation in, 73, 74–76
  - improvement in therapeutic ratio with, 72–74
  - local control in, 84
  - nominal standard dose (NSD) formula in, 71
  - other schemes employing, 81–82
  - patient comfort with, 72
- Radiation Therapy Oncology Group (RTOG) techniques in, 81–82
  - redistributed tumor cells in, 73
  - regenerative response of tumors with, 73–74
  - regional control in, 84
  - survival rates with, 86
  - University of Florida experience with, 82–88
- Radical partial laryngectomy, 43
- Radioactive isotopes, *see* Brachytherapy
- Radionuclide scintigraphy, with thyroid masses, 137
- Radioprotectors, 152
- Radiosensitizers, 152
- Radium needle brachytherapy, 93, 95
- Radon brachytherapy, 93

- Rappaport classification system, for non-Hodgkin's lymphomas, 271–272
- Reconstructive surgery  
 extended vertical partial laryngectomy in, 35–49  
 mandibular, *see* Mandibular reconstruction  
 supraglottic laryngectomy and, 55
- Retinoids  
 differentiation and growth of normal epithelial cells and, 180  
 established squamous cell carcinoma cell lines and, 184–186  
 inhibition of cancer development and growth and, 181–182  
 head and neck cancer and, 177–186  
 premalignant lesions and, 182  
 premalignant oral leukoplakia and, 182–184  
 Rhabdomyosarcoma (RMS), 223; *see also* Orbital rhabdomyosarcoma
- Ruby laser, 61
- Salivary gland tumors  
 lymphoma of extranodal head and neck sites and, 270  
 magnetic resonance imaging (MRI) in, 127, 132–134
- Sample sizes requirements in clinical trials, 198–204
- Scintigraphy  
 cutaneous melanomas of the head and neck with, 249–250  
 thyroid masses with, 137
- Skin cancers  
 argon tunable dye laser system in, 67  
 brachytherapy implants in, 95  
 posterior-lateral neck dissection in, 25  
 retinoids and, 182  
*see also* Cutaneous melanomas of the head and neck
- Skull base malignancies, on magnetic resonance imaging (MRI), 116–124
- Smoking, and head and neck cancer, 177–178, 225
- Socioeconomic status, and orbital rhabdomyosarcoma (RMS), 225, 230
- Spanning devices, in mandibular reconstruction, 2–3
- Spitz nevus, 247
- Split-course radiation  
 accelerated, hyperfractionated radiotherapy with, 79, 80  
 tumor control with, 72
- Squamous carcinoma, extracapsular spread (ECS) of *see* Extracapsular spread (ECS) of squamous carcinoma in cervical metastasis
- Squamous carcinoma, head and neck multimodality treatment in, 143–152  
 natural history of, 177–179
- Squamous carcinoma, laryngeal carbon dioxide laser in, 63–65  
 endoscopic laser excision of early, 64–65
- Squamous carcinoma, oral cavity, and carbon dioxide laser, 65–66
- Squamous carcinoma, oropharyngeal, and hyperfractionated radiotherapy, 76
- Staging  
 combination chemotherapy and, 146–148  
 cutaneous melanomas of the head and neck with, 250–252  
 extracapsular spread (ECS) of squamous carcinoma in cervical metastasis and, 13, 19  
 lymphoma of extranodal head and neck sites with, 275–276  
 metastatic lymph nodes and, 163  
 orbital rhabdomyosarcoma (RMS) and, 229–230
- Sternohyoid myofascial flap, in laryngeal reconstruction, 45–46
- Struts, in mandibular reconstruction, 3–4
- Subacute hemorrhage, on magnetic resonance imaging (MRI), 116
- Submaxillary gland cancer  
 orbital rhabdomyosarcoma (RMS) and, 225  
 suprahyoid neck dissection in, 23
- Sun exposure, and melanoma, 246
- Superficial spreading melanoma (SSM), 247–248, 259–260
- Supraglottic laryngeal cancer  
 extended supraglottic laryngectomy in, 55–57  
 functional neck dissection in, 23  
 supraglottic laryngectomy in, 53–55
- Supraglottic laryngectomy, 52–55  
 anatomic considerations in, 53  
 indications and contraindications for, 53  
 laryngeal reconstruction after, 55  
 surgical techniques in, 53–55
- Suprahyoid neck dissection, 23
- Supraomohyoid neck dissection, 23
- Surgery  
 chemotherapy and extent of, 150–152  
 cutaneous melanomas of the head and neck

- extended supraglottic laryngectomy (ESGL)
    - in, 55–57
  - extended vertical partial laryngectomy (EVPL)
    - in, 32–52
  - extracapsular spread (ECS) of squamous carcinoma in cervical metastasis and, 18
  - general concepts in, 2–3
  - laser surgery in, 61–68
  - mandibular reconstruction in, 1–9
  - modified neck dissection in, 21–29
  - orbital rhabdomyosarcoma (RMS) and, 230–231
  - radiation therapy after, 143–144
  - regional lymphadenectomy in, 22
  - supraglottic laryngectomy in, 52–55
- Tamoxifen, with cutaneous melanomas of the head and neck, 258
- Thoracic inlet lesions, on magnetic resonance imaging (MRI), 137
- Three-quarters extended vertical partial laryngectomy, 33, 44–45
- Thyroglossal duct cysts, on magnetic resonance imaging (MRI), 130
- Thyroid carcinoma
  - extended vertical partial laryngectomy in, 34, 35
  - lower neck dissection in, 25
  - lymphoma of extranodal head and neck sites and, 270
  - magnetic resonance imaging (MRI) in, 134
  - supraglottic laryngectomy in, 53
- Thyroid function tests, with lymphoma of extranodal head and neck sites, 274
- Thyroid lymphoma, 270, 281
- T lymphocytes
  - lymphoma of extranodal head and neck sites and, 273–274
  - clonogenic assay for, 159–163
  - immunomodulation of, 163
  - treatment implications of response of, 164
- Tobacco usage, and head and neck cancer, 177–178
- Tongue cancer
  - brachytherapy in, 95
  - magnetic resonance imaging (MRI) in, 126
  - see also* Base of tongue cancer
- Tonsil, and lymphoma of extranodal head and neck sites, 270
- Tonsillo-palatine implants, 100–101
- Total laryngectomy, 31
- Tracheobronchial squamous metaplasia, and retinoids, 181
- Trapezius scapular osteomyocutaneous flap, in mandibular reconstruction, 6–7
- Tricalcium phosphate, in mandibular reconstruction, 3
- Ultrasonography, with thyroid masses, 137
- Uterine carcinoma, and interferon, 169
- Vaccinia, with cutaneous melanomas of the head and neck, 255
- Vincristine
  - cutaneous melanomas of the head and neck with, 257
  - lymphoma of extranodal head and neck sites and, 279, 280
  - orbital rhabdomyosarcoma (RMS) and, 224, 235–236
- Vitallium mesh crib, in mandibular reconstruction, 4
- Vitallium spanning device, in mandibular reconstruction, 2–3
- Vitamin A (retinol)
  - differentiation and growth of normal epithelial cells and, 180
  - inhibition of cancer development and growth and, 179, 181–182
  - see also* Retinoids
- Vitamin levels, and head and neck cancer, 178
- Vocal cords, and magnetic resonance imaging (MRI), 130
- Waldeyer's ring, and lymphoma of extranodal head and neck sites, 270
- Working Formulation for lymphomas, 273